

ESCCA 2023
Full programme

WEDNESDAY 27 SEPTEMBER 2023

PRE-CONFERENCE PROGRAMME

09:00-13:00 PRE01 Pre-conference workshop: AML-MRD		Mission 1
Organisers: Willemijn Hobo (Nijmegen, NL), Francesco Buccisano (Rome, IT)		
Level: Advanced		
<p>Choice and intensity of treatment of acute myeloid leukemia (AML) patients is based on prognostic risk classification. One of the most important prognostic factors in AML is measurable residual disease (MRD) after intensive chemotherapy. Hence, AML-MRD evaluation has been incorporated in clinical practice to select the appropriate consolidation treatment. Although molecular techniques are available, flow cytometry is the most commonly technique used for AML-MRD assessment. In this course we will present the European Leukemia Net guidelines, discuss the pros and cons of external quality assessment, provide details on key aspects of the pre-analytical phase, and conclude with a hands-on practical session.</p>		
09:00-09:30	ELN Guidelines, recap and future perspectives	Francisco Buccisano (Rome, IT)
09:30-10:00	EQA in MRD: pros and cons	Sylvie Freeman (Birmingham, UK)
10:00-10:30	The importance of preanalytical phase and fluorochrome selection	Tobias Mätzig (Hannover, DE)
10:30-11:00	<i>Coffee break</i>	
11:00-12:00	Practical Session 1	Willemijn Scholten (Amsterdam, NL), Willemijn Hobo (Nijmegen, NL)
12:00-13:00	Practical session 2	Willemijn Scholten (Amsterdam, NL), Willemijn Hobo (Nijmegen, NL)
09:00-13:00 PRE02 Pre-conference workshop: Tips and tricks for optimising instruments and experiments		Mission 2
Organisers: Alfonso Blanco (Dublin, IE), Florian Kern (Brighton, UK)		
Level: Basic-Intermediate		
<p>How confident are you with your flow cytometry data? Are you sure you can reproduce your assay in a different lab? Are you sure that the data that you obtain with your flow cytometer cannot be improved? There are many variables when we are setting up a flow cytometer which can be optimized to improve the quality of your data and its reproducibility, such as panel design, titration of the antibodies, the fluidics of the instrument and or the adjustment of voltages/gains in our flow cytometers. In the same way that a Titration assay, the voltration/gaintration of our instruments will help us to properly distinguish our populations but also to perform a more accurate analysis. These could also help us to improve our compensation matrixes. Therefore, understanding why and how to perform the titration of our reagents as well as a voltration/gaintration of our instruments is a key element for optimising our assays. During this theoretical/practical workshop, we will cover these aspects and participants will see in real samples the big differences in the data between an optimized and a non-optimized assay/instrument.</p>		
09:00-09:15	Opening and Introduction	Alfonso Blanco (Dublin, IE), Florian Kern (Brighton, UK)
09:15 -10:30	Lecture: How to run flow assay correctly	Alfonso Blanco (Dublin, IE)
10:30-11:00	<i>Coffee break</i>	
11:00-13:00	Hands-on: Optimization of your dyes (titration), your instruments (Voltration/Gaintration) and your compensation	Alfonso Blanco (Dublin, IE)

09:00-12:30	PRE03	Pre-conference workshop: A practical guide to monocytosis	Break-out 3
Organiser: Orianne Wagner-Ballon (on behalf of the French group CytHem-LMMC) Level: Intermediate			
The partitioning of peripheral blood monocyte subsets evaluated by flow cytometry, so-called "monocyte assay", is now part of the exploration of monocytosis as it has been demonstrated to be a powerful tool for chronic myelomonocytic leukemia (CMML) diagnosis. The recent 5th edition of the WHO classification identified the monocyte assay as a supporting criteria for CMML diagnosis. In this course we will review the utility of the monocyte assay and its implementation in routine laboratory, including instrument settings, sample preparation, data analysis, interpretation, foremost pitfalls and reporting.			
09:00-09:20		Usefulness of the "Monocyte assay" for monocytosis exploration according to the new WHO classification	Dorothee Selimoglu-Buet (Villejuif, FR)
09:20-09:40		The "Monocyte assay" in routine practice	Orianne Wagner-Ballon (Créteil, FR)
09:40-10:30		First live practice session: data analysis, interpretation and reporting	Sihem Tarfi-Bekkour, Créteil (FR)
10:30-11:00		<i>Coffee break</i>	
11:00-11:30		Highlights on technical and interpretation pitfalls	Orianne Wagner-Ballon, Créteil (FR)
11:30-12:20		Second live practice session: data analysis, interpretation and reporting	Sihem Tarfi-Bekkour, Créteil (FR)
12:20-12:30		Take home messages	Orianne Wagner-Ballon, Créteil (FR)

09:00-12:30	PRE04	Pre-conference workshop: Measurable residual disease in MM	Shuttle
Organiser: Juan A. Flores-Montero (Salamanca, ES) Level: Advanced			
Measurable residual disease (MRD) detection during follow-up is one of the aspects currently drawing more attention in multiple myeloma (MM). Growing evidence is being gathered that confirms the clinical relevance of MRD detection, particularly for the most recent high-sensitive methodologies, as they continue to move closer to the routine clinical laboratory. In this course we will review the utility of MRD detection in clinical practice and, deepen our understanding on the Next Generation Flow methodology by gaining first-hand practical experience on data analysis, interpretation and reporting.			
09:00-09:45		Key aspects of MM MRD data analysis	Juan Flores-Montero (Salamanca, ES)
09:45-10:15		Real life challenges cytometry analyst face. An interactive discussion	Juan Flores-Montero (Salamanca, ES)
10:15-10:30		<i>Coffee break</i>	
10:30-12:30		Live practice session: Next Generation Flow data analysis, interpretation and reporting	Juan Flores-Montero (Salamanca, ES)

Pre-Conference Corporate Satellite Round Table Discussion		Break-out 2
09:30-11:40	Reinvigorating the PNH testing discussion in PNH and BMFS Do you have expertise or interest in paroxysmal nocturnal hemoglobinuria? PNH is a rare and potentially life-threatening blood disease most often diagnosed in individuals between 30 and 50 years of age. It is characterized by complement-mediated damage, leading to symptoms such as anemia, thrombosis, severe infections, and bone marrow failure. GPI deficiency testing by flow cytometry is considered the gold standard for diagnosing PNH and monitoring PNH clone populations. While significant progress has been made in standardizing GPI deficiency testing since the release of the ICCS-ESCCA consensus guidelines, there are still challenges and opportunities to address. During this round table, we will discuss the current PNH testing landscape, including challenges, solutions, and opportunities.	

CONFERENCE PROGRAMME

14:00-15:00	PLE01	Opening & Keynote Lecture 1	Progress
Chairs: Francesco Buccisano (Rome, IT), Florian Kern (Brighton, UK)			
14:00-14:15		Welcome address by the ESCCA President & Announcements	Francesco Buccisano (Rome, IT)
14:15-15:00	PLE01-01	Keynote Lecture: Advances in monitoring immunotherapies (Monitoring) Treg therapy in SOT	Petra Reinke (Berlin, DE)
15:00-15:30	IPP01	ESCCA Industrial Partner Presentation - BD Biosciences	Progress
Chairs: Francesco Buccisano (Rome, IT), Florian Kern (Brighton, UK)			
15:00-15:30		MM MRD analysis using BD technology	Ricarda Schwab (Heidelberg, DE)
15:30-16:00		<i>Coffee break</i>	

16:00-16:30	IPP02	ESCCA Industrial Partner Presentation - Sysmex Europe	Progress
		Chairs: Ulrika Johansson (Bristol, UK) Francesco Buccisano (Rome, IT)	
16:00-16:30		MRD analysis using the XF-1600 flow cytometer	Jordi Petriz (Barcelona, ES)
16:30-18:00	PLE02	ESCCA-ICCS joint session: Standardization in Clinical Flow Cytometry: Design, Validation, and Analysis	Progress
		Chairs: Ulrika Johansson (Bristol, UK), Francesco Buccisano (Rome, IT)	
16:30-17:00	PLE02-01	Using CLSI H62 to Bring Quality to the Clinical Flow Cytometry Laboratory	Virginia Litwin (Montreal, CA)
17:00-17:30	PLE02-02	Education leads to standardization	Ahmad Al-Attar (Worcester, MA, USA)
17:30-18:00	PLE02-03	Standardization in MRD AML	Wolfgang Kern (München, DE)
18:00-19:00		Welcome Reception	Exhibition area

THURSDAY 28 SEPTEMBER 2023

09:30-10:45	PAR01	The WHO2022/ICC new classifications: what has changed in the diagnostic approach to hematological malignancies?	Progress
		Chairs: Ulrika Johansson (Bristol, UK), Willemijn Hobo (Nijmegen, NL)	
09:30-10:00	PAR01-01	New classifications for diagnosis of hematological malignancies: impact on immunophenotyping	Kees Meijer (Groningen, NL)
10:00-10:30	PAR01-02	WHO22/ICC Classifications: Changes in the diagnostic approach to lymphoid neoplasms	Maximiliano Ramia De Cap (Bristol, UK)
10:30-10:45		Q&A	
09:30-10:45	PAR02	Validation and standardisation of functional assays	Mission 1
		Chairs: Marianna Tzanoudaki (Athens, GR), Mirjam van der Burg (Leiden, NL)	
09:30-10:00	PAR02-01	Functional assays of platelet in whole blood	José Enrique O'Connor (Valencia, ES)
10:00-10:30	PAR02-02	Phospho-assays for research and diagnostics of IEI	Hanna IJspeert (Rotterdam, NL)
10:30-10:45		Q&A	
09:30-10:45	PAR03	Towards the definition of the immunological 'normal' across different age groups	Mission 2
		Chairs: Florian Kern (Brighton, UK), Evi Gounari (Thessaloniki)	
09:30-10:00	PAR03-01	Defining the normal: new approaches for harmonized subset definitions and gating procedures	Ester Mejstříková (Prague, CZ)
10:00-10:30	PAR03-02	Minimize technical variation to see a more biological signal - optimized blood sampling methods in Systems Immunology	Jaromir Mikes (Stockholm, SE)
10:30-10:45		Q&A	
10:45-11:15		<i>Coffee break, Exhibition, Posters</i>	
11:15-11:45	IPP03	ESCCA Industrial Partner Presentation - Beckman Coulter	Progress
		Chairs: Enrique O'Connor (Valencia, ES), Ulrika Johansson (Bristol, UK)	
11:15-11:15		HematoFlow revisited: when cytometry becomes a natural extension of hematology analyzers	Olivier Pradier (Brussels, BE)
11:45-12:45	PLE03	ESCCA-EHA joint session: Clinical results in Measurable Residual Disease (MRD)-driven trials	Progress
		Chairs: Francesco Buccisano (Rome, IT), Elizabeth MacIntyre (Paris, FR)	
11:45-12:15	PLE03-01	The role of MRD in current treatment strategies for CLL	Andy Rawstron (Leeds, UK)
12:15-12:45	PLE03-02	Role of minimal residual disease in multiple myeloma: different techniques for a crucial biomarker	Noemi Puig (Salamanca, ES)
12:45-14:00		<i>Lunch break, Exhibition, Posters</i>	
14:00-15:00	PLE04	Selected Best Abstracts	Progress
		Chairs: Francesco Buccisano (Rome, IT), Juan Flores Montero (Salamanca, ES)	
14:00-14:15	PLE04-01	Ultra-sensitive molecular MRD on flow cytometer using superRCA mutation assay	Lei Chen (Uppsala, SE)
14:15-14:30	PLE04-02	Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multi-parameter flow cytometry	Jesse Tettero (Amsterdam, NL)
14:30-14:45	PLE04-03	Detection of MRD in AML with a semi-supervised FlowSOM-KALUZA integrated system with a backgating evaluation capability	George Oudatzis (Athens, GR)
14:45-15:00	PLE04-04	Automated EuroFlow approach for standardized in depth dissection of human circulating B-cells and plasma cells	Alejandro Hernandez-Delgado (Salamanca, ES)

15:00-15:30	IPP04	ESCCA Industrial Partner Presentation - Cytek	Progress
		Chairs: Francesco Buccisano (Rome, IT), Juan Flores Montero (Salamanca, ES)	
15:00-15:30		Design and Optimization of a Multi-Color Panel for Diagnosis and Follow Up of Childhood B Cell Acute Lymphoblastic Leukemias (B-ALL) on the Cytek® Northern Lights™ - CLC Flow Cytometer	Manuel Ramirez (Madrid, ES)
15:30-16:00		<i>Coffee break, Exhibition, Posters</i>	
16:00-17:15	PAR04	Headline 2023 news in cellular therapy of hematological malignancies	Progress
		Chairs: Juan Flores-Montero (Salamanca, ES), Francesco Buccisano (Rome, IT)	
16:00-16:30	PAR04-01	Targeting CD123 from immunotherapy to CART: BPDCN and beyond	Monica Guzman (New York, USA)
16:30-17:00	PAR04-02	CAR T cell treatment for CD19 positive malignancies	Reuben Benjamin (London, UK)
17:00-17:15		Q&A	
16:00-17:15	PAR05	How IVDR will change my lab	Mission 1
		Chairs: Iuri Marinov (Prague, CZ), Frank Preijers (Nijmegen, NL)	
16:00-16:30	PAR05-01	IVDR and flow cytometry: impact on routine diagnostics and clinical trials	Pieter Bogaert (Ghent, BE)
16:30-17:00	PAR05-02	Assessment of Immature PNH RBCs (iRBCs) by Flow Cytometry: Assay Validation following the EU 2017/746-IVDR for In-house Devices	Iuri Marinov (Prague, CZ)
17:00-17:15		Q&A	
16:00-17:15	PAR06	Cytometry in neurological & psychiatric diseases	Mission 2
		Chairs: Florian Kern (Brighton, UK), Willemijn Hobo (Nijmegen, NL)	
16:00-16:30	PAR06-01	Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis	Tilman Schneider-Hohendorf (Münster, DE)
16:30-17:00	PAR06-02	Defining T cells poised to infiltrate the brain and trigger multiple sclerosis	Marvin van Luijn (Rotterdam, NL)
17:00-17:15		Q&A	
17:30-18:30		ESCCA General Assembly	

FRIDAY 29 SEPTEMBER 2023

09:30-10:45	PAR07	Machine learning approaches in flow-cytometry analysis	Progress
		Chairs: Juan Flores-Montero (Salamanca, ES), Evi Gounari (Thessaloniki, GR)	
09:30-10:00	PAR07-01	Translating computational flow cytometry to the clinic	Sarah Bonte (Ghent, BE)
10:00-10:30	PAR07-02	Machine learning for automated FLOW-MRD assessment	Margarita Maurer-Granofszky & Michael Reiter (Vienna, AT)
10:30-10:45		Q&A	
09:30-10:45	PAR08	A practical approach to IVDR	Mission 1
		Chairs: Francesco Buccisano (Rome), Iuri Marinov (Prague, CZ)	
09:30-10:00	PAR08-01	Harmonization efforts in AML MRD	Sylvie Freeman (Birmingham, UK)
10:00-10:30	PAR08-02	Development of full spectrum flow cytometry assays for the detection of measurable residual disease in acute myeloid leukemia	Adrian Schwarzer (Hannover, DE)
10:30-10:45		Q&A	
09:30-10:45	PAR09	Cytometry in the diagnosis of inborn errors of innate immunity	Mission 2
		Chairs: Willemijn Hobo (Nijmegen, NL), Marianna Tzanoudaki (Athens, GR)	
09:30-10:00	PAR09-01	Neutrophil oxidative burst capacity and NK cell function assays in cellular diagnostics	Lisette van de Corput (Utrecht, NL)
10:00-10:30	PAR09-02	Functional studies on inborn errors of innate immunity	Evelien Sprenkeler (Nijmegen, NL)
10:30-10:45		Q&A	
10:45-11:15		<i>Coffee break, Exhibition, Posters</i>	
11:15-12:00	PLE05	ESCCA-ESID joint session	Progress
		Chairs: Willemijn Hobo (Nijmegen, NL), Florian Kern (Brighton, UK)	
11:15-12:00	PLE05-01	B-cell development in a new context: new insights based on inborn errors of immunity	Mirjam van der Burg (Leiden, NL)

12:00-12:30	CL1	Corporate Lecture - Standard Biotools	Progress
		Chairs: Mirjam van der Burg (Leiden, NL), Florian Kern (Brighton, UK)	
12:00-12:30		Standardizing longitudinal and multi-site CAR-T immune-monitoring with ready-to-use and validated 45+ marker flow cytometry panels	Hester Koppejan (NL)
12:30-13:45		<i>Lunch break, Exhibition, Posters</i>	
13:45-14:30	PLE06	Immunology: Interactive Case Presentation	Progress
		Chairs: Alfonso Blanco (Dublin, IE), José Enrique O'Connor (Valencia, ES)	
13:45-14:30	PLE06-01	Interactive cases on inborn errors of immunity	Mirjam van der Burg (Leiden, NL)
14:30-15:30	PLE07	Selected Best Abstracts	Progress
		Chairs: Alfonso Blanco (Dublin, IE), José Enrique O'Connor (Valencia, ES)	
14:30-14:45	PLE07-01	Patients with acute stroke suspicion within 24-hours of symptom onset: monocyte subset profiles in large-vessel-occlusion stroke compared to other diagnosis	Joffrey Ferial (Asnières-sur-Seine, FR)
14:45-15:00	PLE07-02	PIDgeon: Bringing a computational diagnostics pipeline for primary immunodeficiencies closer to the clinic	Annelies Emmaneel (Ghent, BE)
15:00-15:15	PLE07-03	PD1/TIGIT axis in idiopathic pulmonary fibrosis and post-Covid19 pulmonary fibrosis	Sara Gangi (Siena, IT)
15:15-15:30	PLE07-04	Diameters and Fluorescence Calibration for Peripheral Blood Extracellular Vesicle Analyses by Flow Cytometry	Domenico De Bellis (Chieti, IT)
15:30-16:00		<i>Coffee break, Exhibition, Posters</i>	
16:00-17:15	PAR10	Dissecting complexity of Hematological malignancies	Progress
		Chairs: Ulrika Johansson (Bristol, UK), Juan Flores-Montero (Salamanca, ES)	
16:00-16:30	PAR10-01	Phenotypic myeloid alterations in Monoclonal Gammopathy of undetermined significance and in <i>de novo</i> myeloma patients	Lydia Campos (St. Etienne, FR)
16:30-17:00	PAR10-02	Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia	Catia Simoes (Pamplona, ES)
17:00-17:15		Q&A	
16:00-17:15	PAR11	Validation/harmonization of ALL-MRD	Mission 1
		Chairs: Francesco Buccisano (Rome), Sylvie Freeman (Birmingham, UK)	
16:00-16:30	PAR11-01	Standardized flowcytometric MRD analysis in BCP-ALL patients	Vincent van der Velden (Rotterdam, NL)
16:30-17:00	PAR11-02	Challenges in MRD analysis in T-ALL by flow cytometry	Lukasz Sędek (Katowice, PL)
17:00-17:15		Q&A	
16:00-17:15	PAR12	Autoimmunity, chronic inflammatory disease, and immune tolerance	Mission 2
		Chairs: Florian Kern (Brighton, UK), Evi Gounari (Thessaloniki, GR)	
16:00-16:30	PAR12-01	Ag-specific T-cells in autoimmunity	Carina Saggau (Kiel, DE)
16:30-17:00	PAR12-02	Direct isolation of disease-driving T cells in celiac disease without using HLA multimers	Asbjørn Christophersen (Oslo, NO)
17:00-17:15		Q&A	
19:00-23:00		Conference Dinner	Railway Museum
		<i>18:30-19:00 Transfer by bus - departure in front of the NH Hotel</i>	

SATURDAY 30 SEPTEMBER 2023

09:30-10:45	PAR13	New developments PNH treatment and diagnostics	Progress
		Chairs: Iuri Marinov (Prague, CZ), Francesco Buccisano (Rome, IT)	
09:30-10:00	PAR13-01	Developments in diagnostics to monitor PNH clones and complement activation	Frank Preijers (Nijmegen, NL)
10:00-10:30	PAR13-02	Modern treatment approaches to PNH treatment	Bruno Fattizzo (Milan, IT)
10:30-10:45		Q&A	
09:30-10:45	PAR14	Validated approach to T-cell/B-cell lympho-proliferative disorders diagnosis and monitoring	Mission 1
		Chairs: Ulrika Johannson (Bristol, UK), Willemijn Hobo (Nijmegen, NL)	
09:30-10:00	PAR14-01	New flow-cytometry approaches for diagnosis (of clonality), classification and monitoring of T-cell CLPD	Julia Almeida (Salamanca, ES)
10:00-10:30	PAR14-02	B-LPD, diagnosis beyond typical immunophenotypic fingerprint entities	Massimo Geuna (Turin, IT)
10:30-10:45		Q&A	
09:30-10:45	PAR15	Clinical cytometry in transplantation	Mission 2
		Chairs: Florian Kern (Brighton, UK), Marianna Tzanoudaki (Athens, GR)	
09:30-10:00	PAR15-01	Immunological differences between heart- and kidney-transplanted children	Britt-Marie Ekman-Joelsson (Göteborg, SE)
10:00-10:30	PAR15-02	Direct detection of single extracellular vesicles in kidney transplantation	Wouter Woud (Rotterdam, NL)
10:30-10:45		Q&A	
10:45-11:15		<i>Coffee break, Exhibition, Posters</i>	
11:15-12:00	PLE08	Keynote Lecture 2	Progress
		Chairs: Juan Flores-Montero (Salamanca, ES), Francesco Buccisano (Rome, IT)	
11:15-12:00	PLE08-01	Dissecting MM: from flow-cytometry to single-cell sequencing	Bruno Paiva (Pamplona, ES)
12:00-12:45	PLE09	Hemato-Oncology: Interactive Case Presentations	Progress
		Chairs: Juan Flores-Montero (Salamanca, ES), Francesco Buccisano (Rome, IT)	
12:00-12:45	PLE09-01	Interactive Case Presentation: Breast cancer with the presence of a large number of atypical cells in peripheral blood mimicking acute myeloid leukemia: a case report	Arianna Gatti (Legnano, IT)
12:45-13:00	PLE10	ESCCA Awards session & Closure	Progress
		Chairs: Juan Flores-Montero (Salamanca, ES), Francesco Buccisano (Rome, IT)	
		Best Oral Presentation & Best Poster Awards	
		ESCCA 2024	
		Closing Address	